Prognostic and therapeutic potential of imbalance between PD ‐1+ CD8 and ICOS +Treg cells in advanced HBV ‐ HCC
Cancer Science · 2024-08 · 115 (8) · 2553-2564
DOI: 10.1111/cas.16247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 15.06.2024. Verfasst von Fengna Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, CD8-Positive T-Lymphocytes, Inducible T-Cell Co-Stimulator Protein, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Training Fund for Open Projects at Clinical Institutes and Departments of Capital Medical University, The science fundation of Beijing Ditan Hospital, Capital Medical University.
Abstract (Originalsprache)
Over 50% of patients with hepatitis B virus‐associated hepatocellular carcinoma (HBV‐HCC) are diagnosed at an advanced stage, which is characterized by immune imbalance between CD8+ T cells and regulatory T (Treg) cells that accelerates disease progression. However, there is no imbalance indicator to predict clinical outcomes. Here, we show that the proportion of CD8+ T cells decreases and Treg cells increases in advanced HBV‐HCC patients. During this stage, CD8+ T cells and Treg cells expressed the coinhibitory molecule PD‐1 and the costimulatory molecule ICOS, respectively. Additionally, the ratio between PD‐1+CD8 and ICOS+Tregs showed significant changes. Patients were further divided into high‐ and low‐ratio groups: PD‐1+CD8 and ICOS+Tregs high‐ (PD‐1/ICOS hi ) and low‐ratio (PD‐1/ICOS lo ) groups according to ratio median. Compared with PD‐1/ICOS lo patients, the PD‐1/ICOS hi group had better clinical prognosis and weaker CD8+ T cells exhaustion, and the T cell‐killing and proliferation functions were more conservative. Surprisingly, the small sample analysis found that PD‐1/ICOS hi patients exhibited a higher proportion of tissue‐resident memory T (T RM ) cells and had more stable killing capacity and lower apoptosis capacity than PD‐1/ICOS lo advanced HBV‐HCC patients treated with immune checkpoint inhibitors (ICIs). In conclusion, the ratio between PD‐1+CD8 and ICOS+Tregs was associated with extreme immune imbalance and poor prognosis in advanced HBV‐HCC. These findings provide significant clinical implications for the prognosis of advanced HBV‐HCC and may serve as a theoretical basis for identifying new targets in immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
- Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
- Beijing Institute of Infectious Diseases, Beijing, China.
ORCID-Profile: Xianbo Wang
Förderung
- Training Fund for Open Projects at Clinical Institutes and Departments of Capital Medical University
- The science fundation of Beijing Ditan Hospital, Capital Medical University
Zitieren
APA
Yan, F., Zhu, B., Shi, K., Zhang, Y., Zeng, X., Zhang, Q., Yang, Z., & Wang, X. (2024). Prognostic and therapeutic potential of imbalance between PD ‐1+ CD8 and ICOS +Treg cells in advanced HBV ‐ HCC. Cancer Science, 115(8), 2553-2564. https://doi.org/10.1111/cas.16247
Vancouver
Yan F, Zhu B, Shi K, Zhang Y, Zeng X, Zhang Q, et al. Prognostic and therapeutic potential of imbalance between PD ‐1+ CD8 and ICOS +Treg cells in advanced HBV ‐ HCC. Cancer Science. 2024;115(8):2553-2564. doi:10.1111/cas.16247
BibTeX
@article{Yan2024,
author = {Yan, Fengna and Zhu, Bingbing and Shi, Ke and Zhang, Yi and Zeng, Xuanwei and Zhang, Qun and Yang, Zhiyun and Wang, Xianbo},
title = {Prognostic and therapeutic potential of imbalance between PD ‐1+ CD8 and ICOS +Treg cells in advanced HBV ‐ HCC},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {8},
pages = {2553--2564},
doi = {10.1111/cas.16247}
}
EUVIMED